|
 |
FactiveThis page contains recent news articles, when available, and an overview of Factive but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Factive (when available) Gemifloxacin is a quinolone/fluoroquinolone antibiotic. Gemifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Gemifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. For the treatment of Bacterial infection caused by susceptible strains such as S.pneumoniae, H.influenzae, H.parainfluenzae, or M.catarrhalis, S.pneumoniae (including multi-drug resistant strains [MDRSP]), M.pneumoniae, C.pneumoniae, or K.pneumoniae. Mechanism Of Action: The bactericidal action of Gemifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. News Articles on Gemifloxacin Cornerstone Therapeutics Reports Third Quarter 2009 Financial Results - Nov 4, 2009 ..."In the third quarter, we continued to execute our strategy with the additions of Curosurf and Factive to our product portfolio," said Craig A. Collard, ... Reuters Cornerstone Tops Zacks Ests - Nov 11, 2009 Factive contributed $91000 to third quarter revenue. Product rights for the candidate and related inventory were acquired in September. ... Zacks.com Cornerstone Therapeutics Reports Third Quarter 2009 Financial Results - Nov 4, 2009 ..."In the third quarter, we continued to execute our strategy with the additions of Curosurf and Factive to our product portfolio," said Craig A. Collard, ... MSN Money Cornerstone Therapeutics reports Q3 net loss - Nov 6, 2009 Craig Collard, chairman and CEO of Cornerstone, said: "In the third quarter, we continued to execute our strategy with the additions of Curosurf and Factive ... American Chronicle … , Oscient Pharmaceuticals launch antibiotic FACTIVE tablets in... - Oct 5, 2006 ...- Pfizer Inc's Mexican unit Pfizer SA de CV is launching FACTIVE tablets, Oscient Pharmaceuticals Corporation's lead antibiotic product, in Mexico, ... Forbes Oscient, Pfizer get Mexican health ministry approval for Factive antib... - Aug 1, 2006 LONDON (AFX) - Oscient Pharmaceuticals Corporation said its antibiotic Factive has been approved by the Ministry of Health in Mexico as a five-day treatment ... Forbes Oscient gets wider approval for Factive - May 2, 2007 Oscient Pharmaceuticals Corp. said today it has gotten US regulatory approval for wider use of its Factive tablets as a pneumonia treatment. ... Boston Globe Oscient expands Factive to Canada - Mar 2, 2007 The Waltham drug maker said today Abbott Canada, an affiliate of Abbott Inc., are now selling the firm's Factive tablets, a five-day treatment for acute ... Boston Globe FDA panel frowns on Factive - Sep. 12, 2006 - Sep 12, 2006 By Aaron Smith, CNNMoney.com staff writer. NEW YORK (CNNMoney.com) -- A panel of FDA advisers suggested that the agency not approve a biotech's drug for ... CNNMoney.com … in Pivotal Phase III Clinical Trial of FACTIVE Tablets for... - Mar 9, 2005 ..."Our plans to expand the labeling for FACTIVE are underway and the completion ... Even if we succeed in launching FACTIVE tablets, a number of factors could ... RedOrbit FDA tells Oscient to revise Factive label, warnings - Jul 8, 2008 Oscient Pharmaceuticals Corp. has received notice from federal regulators to revise the usage and warning labels of its blockbuster Factive pneumonia and ... Bizjournals.com Oscient Pharma shrs fall on weak Q1 revenue view - Apr 16, 2008 ..."While quarterly revenue fluctuates due to the timing of shipments and wholesaler buying patterns, as well as the seasonality of Factive, we remain on track ... Reuters FDA Advisers Oppose Wider Label For Factive In Sinusitis - Sep 13, 2006 By Aaron Lorenzo. GAITHERSBURG, Md. - The FDA's Anti-Infective Drugs Advisory Committee voted against expanding the label for Factive (gemifloxacin) to ... BioWorld Online - BioWorld Online Oscient Pharma sees Q1 rev of $23 mln - Apr 11, 2007 Oscient Pharmaceuticals said it expects Antara to contribute about $12 million and its antibiotic Factive to add about $11 million to revenue in the first ... Reuters Regulatory Filing for FACTIVE Tablets Submitted in Europe - May 7, 2008 Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI) commercialization partner for FACTIVE(R) (gemifloxacin mesylate) tablets, Menarini Group, ... Genetic Engineering News - Genetic Engineering News (press release) Oscient says Factive sales to be $5 million in first quarter - Apr 6, 2005 Oscient Pharmaceuticals Corp. said it expects to report first-quarter sales of about $5 million from its main product and said that extensive promotional ... Boston Business Journal FDA experts to vote on sinus drug Factive - Sep. 8, 2006 - Sep 8, 2006 By Aaron Smith, CNNMoney.com staff writer. NEW YORK (CNNMoney.com) -- A small biotech could get a big boost from the FDA next week, if a panel of expert ... CNNMoney.com Bloomberg Printer-Friendly Page - Dec 3, 2007 FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic ... Oscient promotes ANTARA and FACTIVE through a nationwide sales force ... Bloomberg Oscient Pharmaceuticals completes Factive sales force expansion in... - Mar 18, 2005 Oscient Pharmaceuticals Corp (Oscient) has completed the expansion of its primary care sales force with the hiring of 150 new sales representatives. ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Antibiotics can harm tendons, FDA warns - Jul 8, 2008 The so-called black box warning would also apply to Bayer's Avelox, Oscient Pharmaceuticals Corp's Factive, Daiichi Sankyo Co Ltd's Floxin, ... Reuters Oscient Pharmaceuticals Amends FACTIVE License Agreement with LG … - Dec 29, 2006 WALTHAM, Mass. -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) has amended its license and option agreement with LG Life Sciences, ... Free with registration - Business Wire - AccessMyLibrary.com Oscient issues forecast - Oct 10, 2007 Oscient said it expects to record about $12.5 million in revenue from Antara and about $3 million from Factive, a treatment for acute bacterial ... Boston Globe Factive.(Used to treat infections of the respiratory tract, such as... - Dec 1, 2005 Factive is an antibiotic that is used to treat infections of the respiratory tract, such as bronchitis and pneumonia. Medications similar to Factive have ... Free with registration - PDR Family Guide to Prescription Drugs - AccessMyLibrary.com Regulatory Filing For FACTIVE Tablets Submitted In Europe - May 9, 2008 Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI) commercialization partner for FACTIVE® (gemifloxacin mesylate) tablets, Menarini Group, ... Medical News Today - Medical News Today (press release) Oscient Pharma sees fourth-quarter revenue at $18 mln - Jan 8, 2007 The company said it expects $12 million from its cardiovascular product Antara, and about $6 million from Factive, an antibiotic for chronic bronchitis and ... Reuters Oscient Gets Approvable Letter - Sep 22, 2006 Oscient Pharmaceuticals(OSCI Quote) received a request from regulators for additional information on its pneumonia drug Factive. ... TheStreet.com - TheStreet.com (subscription) … Primary Endpoint in Phase III Trial of FACTIVE Tablets for... - Jun 6, 2005 ..."FACTIVE was sufficiently potent to allow treatment of patients for only five days ... "We believe that a five-day course of therapy with FACTIVE has the ... RedOrbit Oscient Pharmaceuticals Reports Financial Results for First Quarter... - May 2, 2007 This decrease reflects completion of enrollment in the FACTIVE ... Oscient granted commercialization rights for FACTIVE to Abbott Canada in August of last ... Free with registration - Business Wire - AccessMyLibrary.com Brandeis business school names Dolbear acting dean - Sep 13, 2006 Oscient Pharmaceuticals Corp. of Waltham failed to win a US advisory panel's backing for extending the marketing of the company's Factive antibiotic to ... Boston Globe Clinical Data on FACTIVE(R) Tablets to be Presented at the 43rd... - Oct 7, 2005 WALTHAM, Mass.--(BUSINESS WIRE)--Sept. 30, 2005--Oscient Pharmaceuticals' (Nasdaq: OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin ... businesswire.com Oscient Pharma narrows 4th-qtr loss, shares jump - Feb 27, 2007 ...$18.3 million as the company recorded $12.5 million from the sales of Antara and $5.5 million from its antibiotic Factive, Oscient said in a statement. ... Reuters … Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in Canada - Aug 22, 2006 MONTREAL and WALTHAM, Mass.--(BUSINESS WIRE)--Abbott Canada, the Canadian affiliate of Abbott, has launched Oscient Pharmaceuticals Corporation's (Nasdaq: ... businesswire.com Clinical Data on FACTIVE(R) Tablets to Be Presented at the 43rd... - Sep 30, 2005 Oscient Pharmaceuticals' (Nasdaq: OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin mesylate) tablets, is the subject of two poster ... RedOrbit Oscient Pharma narrows loss on Factive sales - Mar 6, 2006 Revenue growth from the launch of its bronchitis treatment drug Factive helped Oscient Pharmaceuticals Corp. narrow its net loss to $17.1 million during the ... Bizjournals.com Oscient reports preliminary 2q revenues - Jul 13, 2007 Oscient also sells Factive, a treatment for certain types of bronchitis and pneumonia; Factive is expected to generate about $1.5 million in second-quarter ... Boston Globe Oscient Pharmaceuticals Reports Financial Results for Fourth Quarter ... - Feb 28, 2005 Since the launch of FACTIVE, the Company shipped $5.4 million in product ... For the quarter ended December 31, 2004, orders for FACTIVE continued to be ... Free with registration - Business Wire - AccessMyLibrary.com … Enter into Commercialization Agreement for FACTIVE Tablets; FACTIVE... - Aug 10, 2006 FACTIVE is currently approved in Canada for the five-day treatment of acute bacterial ... FACTIVE was approved by Health Canada for the treatment of AECB. ... RedOrbit Tendon tears after drug use - Jan 15, 2008 Fluoroquinolone antibiotics, prescribed for bacterial infections, include ciprofloxacin (Cipro), gatifloxacin, gemifloxacin (Factive), ... Albany Times Union Oscient sounds out notes with SEC - Mar 15, 2007 The Waltham company markets such drugs as Antara, used to treat high cholesterol, and Factive, used in treatment of chronic bronchitis. ... Boston Globe New Data on FACTIVE(R) Tablets and Ramoplanin Presented at the 45th … - Dec 16, 2005 Oscient Pharmaceuticals' (Nasdaq: OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin mesylate) tablets, and lead product candidate, ... businesswire.com FDA ACCEPTS OSCIENT'S RESPONSE TO FACTIVE APPROVABLE … - Nov 29, 2006 The FDA has accepted Oscient Pharmaceuticals' complete response to the approvable letter for the application seeking approval of Factive (gemifloxacin ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones LegalView Reveals Details of the FDA Mandated Black Box - Jul 11, 2008 Among the most common of the fluoroquinolone antibiotics are Levaquin, Cipro, Factive and Avelox - some of the most commonly prescribed anti-bacterial drugs ... TransWorldNews - TransWorldNews (press release) Berg, Glickman join Oscient - Aug 23, 2007 Oscient markets such drugs as Antara, for high blood pressure, and Factive, an antibiotic for the treatment of acute bacterial exacerbations of chronic ... Boston Globe Auxilium signs promotional deal for Testim product - Apr 13, 2005 ...using its 250-person sales force, currently promoting Factive, a treatment for chronic bronchitis and mild to moderate community-acquired pneumonia. ... Bizjournals.com Oscient Pharmaceuticals Announces Determination of the Consideration ... - Nov 20, 2008 FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic ... Oscient promotes ANTARA and FACTIVE through a national sales force ... International Business Times FDA advisers oppose wider label for Factive.(Wednesday, Sept.... - Sep 18, 2006 The FDA's Anti-Infective Drugs Advisory Committee voted against expanding the label for Factive (gemifloxacin) to include acute bacterial sinusitis, ... Free with registration - BioWorld Week - AccessMyLibrary.com … Antimicrobial Chemotherapy Highlights Study of FACTIVE(R) Tablets... - Jun 12, 2007 The data from the Phase III clinical trial comparing a five-day and seven-day course of treatment with FACTIVE for CAP formed the basis of the approval last ... Genetic Engineering News - Genetic Engineering News (press release) Full Results Released From Phase III Trial Comparing Five-Day and … - Sep 18, 2005 These encouraging data support the potential use of FACTIVE, the most potent ... FACTIVE was well-tolerated in the study, with a low withdrawal rate due to ... RedOrbit Oscient Pharmaceuticals Amends Exchange Offer - Nov 7, 2008 FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic ... Oscient promotes ANTARA and FACTIVE through a national sales force ... International Business Times Q2 2007 Oscient Pharmaceuticals Corporation Earnings Conference Call ... - Aug 2, 2007 On the other hand, our FACTIVE prescriptions experienced a more pronounced ... Nonetheless, the FACTIVE brand generated $12.7 million in revenues for the ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Oscient Pharmaceuticals Commences Exchange Offer - Oct 21, 2008 FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic ... Oscient promotes ANTARA and FACTIVE through a national sales force ... Genetic Engineering News - Genetic Engineering News (press release) Q1 2005 Oscient Pharmaceuticals Corporation Earnings Conference Call ... - May 2, 2005 Also, we'd like to note that FACTIVE tablets should only be used to treat infections ... For important information concerning the safety and use of FACTIVE, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com FACTIVE(R) Tablets Subject of Five Presentations at Third Internationa... - Oct 9, 2006 NIAGARA-ON-THE-LAKE, ONTARIO, Canada -- FACTIVE(R) (gemifloxacin mesylate) tablets, Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI) lead antibiotic ... Free with registration - Business Wire - AccessMyLibrary.com … Pharmaceuticals Completes Enrollment in Phase IV Trial of FACTIVE ... - Jan 26, 2007 Known as the FORCE trial (FACTIVE Outpatient Respiratory Infection Community Experience), Oscient began enrollment coincident with the launch of FACTIVE in ... Genetic Engineering News - Genetic Engineering News (press release) Q4 2005 Oscient Pharmaceuticals Corporation Earnings Conference Call ... - Mar 6, 2006 In addition to making good progress in prescription growth for FACTIVE and ... We aim to further differentiate FACTIVE by seeking new treatment claims and ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Oscient Pharmaceuticals' FACTIVE Tablets Subject of Poster … - Apr 4, 2006 Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI) lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, is the subject of two poster presentations at ... RedOrbit Oscient raises $36M through private placement - Apr 12, 2006 Government regulators have approved Factive in tablet form to treat acute bronchitis and pneumonia. The company is also developing an intravenous form of ... Bizjournals.com Oscient Pharmaceuticals' Board of Directors Names 25-Year Lilly... - Jan 10, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Free with registration - Business Wire - AccessMyLibrary.com … and Pfizer Enter Agreement for FACTIVE Tablets in Mexico - Feb 7, 2006 FACTIVE is currently approved in the US for the treatment of ... "FACTIVE represents an important addition to our antibiotic portfolio in Mexico," stated ... RedOrbit Oscient Pharmaceuticals Reports Financial Results for Third Quarter... - Nov 9, 2006 ..."During the third quarter, we accomplished several important milestones for FACTIVE. We sublicensed the rights to FACTIVE in Canada to Abbott Canada, ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals Corporation at JPMorgan 25th Annual … - Jan 1, 2007 FACTIVE is our second product which we launched in September of 2004. ... We'd just launched FACTIVE. Last year we had our first full year of results. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Data on FACTIVE(R) Tablets Short-Course Therapy in Patients with Co- … - Oct 13, 2006 TORONTO -- Data presented at the 44th Annual Meeting of the Infectious Diseases Society of America (IDSA) examined the outcome of short-course treatment ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals Reports Third Quarter 2008 Financial Results - Nov 4, 2008 Revenues from the antibiotic FACTIVE ® (gemifloxacin mesylate) tablets totaled $3.7 ... The Company expects 2008 revenue from ANTARA and FACTIVE to be ... International Business Times Oscient Pharmaceuticals Announces Meeting Date for FDA Advisory … - Jun 28, 2006 The ABS sNDA seeks approval for the treatment of this infection with FACTIVE in a five-day treatment regimen. The sNDA contains data from five Phase III ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals Corporation at JPMorgan 25th Annual … - Jan 11, 2007 FACTIVE is our second product which we launched in September of 2004. ... We'd just launched FACTIVE. Last year we had our first full year of results. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Oscient Pharmaceuticals Completes Sales Force Expansion; Company … - Oct 3, 2005 ..."After exploring co-promotion partnerships for FACTIVE with a number of ... The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, ... $4.95 - Business Wire - ECNext Q2 2006 Oscient Pharmaceuticals Corporation Earnings Conference Call ... - Aug 8, 2006 Whether we'll be able to expand the indications which FACTIVE has approved ... There are strong overlap between the Antara and FACTIVE target physician and ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com OSCIENT COMPLETES ENROLLMENT IN PHASE IV OF FACTIVE … - Mar 1, 2007 Oscient Pharmaceuticals Corporation (Nasdaq: OSCI), Waltham, Mass., has completed enrollment in its Phase IV post-marketing trial for its fluoroquinolone ... $4.95 - Biotech Business - ECNext Q3 2005 Oscient Pharmaceuticals Corporation Earnings Conference Call ... - Nov 2, 2005 For important information regarding the safety and use of FACTIVE please see ... This is the same pattern that we saw with FACTIVE during our first year. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Oscillating Oscient - May 7, 2007 The company's antibiotic Factive generated a 20% increase in ... The company has collaborations for Factive with Inside Value pick Pfizer (NYSE: PFE) in ... fool.com Oscient Pharmaceuticals Reports Second Quarter 2008 Financial Results - Aug 1, 2008 FACTIVE prescription performance: Based on Wolters Kluwer Health monthly ... FACTIVE is approved for the treatment of acute bacterial exacerbations of ... Genetic Engineering News - Genetic Engineering News (press release) … : FDA OKs Iomai trial; Agency panel to review Factive; Curis opens... - Sep 11, 2006 Trading in shares of Oscient Pharmaceuticals was suspended in advance of an FDA panel meeting to consider expanding the use of Factive tablets to treat ... FierceBiotech Reverse Split of Oscient Pharmaceuticals Stock to Be Effected with... - Nov 15, 2006 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com … for Community-Acquired Pneumonia Highlight Utility of FACTIVE Table... - Feb 22, 2007 FACTIVE is approved in the US for the seven-day treatment of mild to moderate ... FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for ... $4.95 - Business Wire - ECNext Oscient amends Factive deal with LG Life Sciences.(Oscient … - Jan 8, 2007 Oscient Pharmaceuticals has amended its license and option agreement with fellow USA-based LG Life Sciences for its oral antibiotic Factive (gemifloxacin ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Oscient Paying Reliant $78M For Cholesterol Drug In US - Jul 26, 2006 Antara, which has garnered about $35 million in revenue for Reliant over the past 12 months, will be marketed by Oscient's sales force along with Factive ... BioWorld Online - BioWorld Online Oscient Pharmaceuticals Provides Preliminary Revenue Results for... - Oct 11, 2006 ..."We look forward to building momentum with FACTIVE as we enter the ... During the third quarter, over 49500 prescriptions for FACTIVE were written ... Genetic Engineering News - Genetic Engineering News (press release) Most Popular factive Story - Nov 26, 2006 ...> The FDA has granted fast-track status to Pharmaxis' Bronchitol as a therapy for cystic fibrosis. Investors applauded the news by driving up the value of ... FierceBiotech … and Abbott Canada enter into agreement for Factive tablets, launch... - Sep 5, 2006 Factive is currently approved in Canada for the five-day treatment of acute bacterial ... Factive was approved by Health Canada for the treatment of AECB. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Antibiotics Called Fluoroquinolones Can Cause Tendonitis and Tendon … - Jul 30, 2008 The antibiotics to watch for include: Cipro, Cipro XR, Proquin XR, Factive, Levaquin Avelox, Noroxin and Floxin. The Anti-Aging Bottom Line: More forceful ... Stop Aging Now Oscient and LG amend Factive agreement - Apr 7, 2005 Massachusetts-based biopharmaceutical firm Oscient Pharmaceuticals Corporation has amended its license and option agreement with Korea's LG Life Sciences ... Pay-Per-View - Datamonitor News and Comment - Factiva, from Dow Jones … Halted Today; FDA Advisory Committee to Discuss FACTIVE(R) sNDA... - Sep 12, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext … company completes enrollment in phase III FACTIVE trial for... - Apr 4, 2005 ..."Our plans to expand the labeling for FACTIVE are underway and the completion of enrollment in this trial represents another key step in our effort to ... Pay-Per-View - Biotech Business Week - Factiva, from Dow Jones Pfizer Acquires Rights to Oscient Antibiotic in Mexico - Feb 9, 2006 Factive (gemifloxacin mesylate) is currently approved in the US for the ... "Our business strategy, outside of the US, is to build the Factive brand through ... RedOrbit Oscient Pharmaceuticals Receives Notice of Allowance for Ramoplanin … - Sep 7, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com Factive.(Recommendations against approval) - Oct 1, 2006 Gemifloxacin (Factive, Oscient Pharmaceuticals) as a 5-day treatment for acute bacterial sinusitis. Free with registration - Formulary - AccessMyLibrary.com Williams-Labadie Wins Prestigious Manny Award. - May 8, 2007 FACTIVE is an antibiotic used to treat adults 18 years or older with ... FACTIVE is a registered trademark of Oscient Pharmaceuticals Corporation. ... Free with registration - PR Newswire - AccessMyLibrary.com Oscient Pharmaceuticals to Present at 24th Annual JPMorgan Healthcare... - Jan 9, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... businesswire.com Oscient completes Ph IV enrollment in Factive trial early. - Feb 5, 2007 Oscient completes Ph IV enrollment in Factive trial early. Oscient Pharmaceuticals has completed enrollment in its Phase IV post-marketing trial for its ... $9.94 - Pharma Marketletter - Alacra Store … company completes enrollment in phase III FACTIVE trial for... - Apr 10, 2005 ..."Our plans to expand the labeling for FACTIVE are underway and the completion of enrollment in this trial represents another key step in our effort to ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Webcast Alert: Oscient Pharmaceuticals to Present at the 9th Annual … - Nov 8, 2007 FACTIVE ® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... businesswire.com Press Release: Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five- … - May 2, 2007 Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia Receives FDA Approval. from M2 Presswire. Pay-Per-View - M2 Presswire - HighBeam Research Oscient Pharmaceuticals Announces Pricing of $60 Million in Principal... - Apr 25, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals "strong buy," target price reduced - May 29, 2008 While Factive sales were adversely impacted by a mild early winter, sales are likely to be picking up on account of the severe weather in early 2007, ... newratings.com Oscient Pharmaceuticals to Present at Roth Capital Partners 18th... - Feb 21, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... businesswire.com Oscient Pharmaceuticals downgraded to "neutral weight" - update - Nov 10, 2006 In a research note published this morning, the analyst mentions that the company announced on Tuesday that it would promote FACTIVE itself, indicating its ... newratings.com Oscient completes Factive sales force expansion.(Oscient … - Mar 28, 2005 USA-based Oscient Pharmaceuticals says it has completed the expansion of its primary-care sales force with the hiring of 150 new representatives. ... $4.95 - Pharma Marketletter - ECNext Oscient must supply more information on Factive, says FDA - Sep 25, 2006 The FDA has asked Oscient Pharmaceuticals to provide additional information to support its application for pneumonia drug Factive. ... Pay-Per-View - Datamonitor News and Comment - Factiva, from Dow Jones Factive gets approvable letter in pneumonia.(Monday, Sept. 25) - Oct 2, 2006 Factive (gemifloxacin) will get an expanded label in pneumonia, according to an FDA approvable letter. Oscient Pharmaceuticals Corp., the maker of Factive, ... Pay-Per-View - BioWorld Week - Factiva, from Dow Jones Oscient Pharmaceuticals Reports Financial Results for First Quarter... - Mar 31, 2007 This decrease reflects completion of enrollment in the FACTIVE ... Oscient granted commercialization rights for FACTIVE to Abbott Canada in August of last ... businesswire.com Oscient Pharmaceuticals Hires Nick Colangelo as Senior Vice President... - Jan 4, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext … Pliva; Synta touts new data; regulators question Factive rashes;and... - Sep 10, 2006 The FDA's regulatory staff has raised questions about the risk of skin rashes from Oscient's Factive antibiotic. Report ... FierceBiotech Oscient's Factive effective in five-day dosing regime.(Oscient … - Jun 13, 2005 Preliminary analysis of a pivotal, double-blind Phase III trial of Oscient Pharmaceuticals' Factive (gemifloxacin mesylate) tablets for the five-day ... $4.95 - Pharma Marketletter - ECNext Factive. - Jun 1, 2007 Gemifloxacin (Factive, Oscient) was approved for the 5-day treatment of community-acquired pneumonia of mild-to-moderate severity. This agent was previously ... $9.94 - Formulary - Alacra Store Brand Names/Synonyms: Factive is also known by the following brand names and/or synonymsFactive; Gemifloxacin; Gemifloxacin Mesilate; Gemifloxacin [Inn] Drug Category: Factive is categorized under the following by the FDA: Anti-bacterial Agents; ATC:J01MA15 Dosage Forms: TABLET Absorption: Gemifloxacin is rapidly absorbed from the gastrointestinal tract. The absolute bioavailability of the 320 mg tablet averaged approximately 71% (95% CI 60%-84%). Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 1-acetyloxycyclohexane-1-carboxylicacid |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |